Delia Garcia
Family · San Antonio, TXNPI 1962139345
Payments from drug & device makers
Across 801 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Cequr Corporation$1K
- Boehringer Ingelheim$1K
- Corcept Therapeutics$945
- Dexcom, Inc.$907
- plus $8K from 34 others
What the payments were for
- Food & beverage$15,447100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 96 | $1,745 |
| Novo Nordisk | 89 | $1,616 |
| Cequr Corporation | 4 | $1,125 |
| Boehringer Ingelheim | 56 | $1,046 |
| Corcept Therapeutics | 46 | $945 |
| Dexcom, Inc. | 58 | $907 |
| Novartis | 61 | $887 |
| Mannkind Corporation | 61 | $881 |
| Ascensia Diabetes Care US Inc. | 34 | $808 |
| Amgen | 41 | $594 |
| Medtronic | 25 | $574 |
| Radius Health, Inc. | 29 | $525 |
| AstraZeneca(2 entities) | 25 | $481 |
| Xeris Pharmaceuticals, Inc. | 24 | $433 |
| Bayer | 23 | $398 |
| Sanofi-aventis U.S. LLC | 18 | $382 |
| Recordati_rare_diseases_inc. | 22 | $366 |
| AbbVie | 27 | $362 |
| Kyowa Kirin, Inc. | 14 | $333 |
| Insulet Corporation | 7 | $252 |
| Soleno Therapeutics, Inc. | 4 | $113 |
| Neurocrine Biosciences, Inc. | 4 | $96 |
| Madrigal Pharmaceuticals | 3 | $79 |
| Sequel Med Tech, LLC | 3 | $59 |
| Tolmar, Inc. | 4 | $56 |
| Ipsen Biopharmaceuticals, Inc | 3 | $54 |
| Merck | 3 | $54 |
| Almatica Pharma LLC | 2 | $46 |
| Averitas Pharma Inc. | 2 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $32 |
| Pfizer | 2 | $28 |
| BETA Bionics, Inc. | 2 | $26 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$1,058
- Korlym$213
- MINIMED 780G$160
- Omnipod$147
- Ozempic$125
- DEXCOM G6 TRANSMITTER$122
- MINIMED 770G$120
- MOUNJARO$117
How this compares
$15,490 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 654 | $828,426 |
| MounjaroTirzepatide | 367 | $453,790 |
| JardianceEmpagliflozin | 224 | $316,127 |
| FarxigaDapagliflozin Propanediol | 193 | $237,715 |
| TrulicityDulaglutide | 136 | $215,320 |
| AfrezzaInsulin Regular, Human | 73 | $184,137 |
| Tresiba Flextouch U-100Insulin Degludec | 90 | $73,450 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $61,496 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $61,479 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $61,447 |
| VascepaIcosapent Ethyl | 77 | $52,844 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $46,320 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $42,704 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $38,744 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $38,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Xultophy 100-3.6 | $1,616 | $933,930754 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,745 | $691,448595 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $1,046 | $388,999273 claims |
| AstraZenecaFarxiga | $481 | $237,715193 claims |
| Mannkind CorporationAfrezza | $881 | $184,13773 claims |
| MerckJanuvia | $54 | $35,61029 claims |
| Cequr CorporationCequr Simplicity | $1,125 | $22,71428 claims |
| AmgenProlia | $594 | $22,04113 claims |
| AbbVieSynthroid | $362 | $7,31176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.